Clinical Trial Detail

NCT ID NCT04014205
Title A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Beijing InnoCare Pharma Tech Co., Ltd.
Indications

marginal zone B-cell lymphoma

CLL/SLL

follicular lymphoma

mantle cell lymphoma

Therapies

Orelabrutinib

Age Groups: senior adult

No variant requirements are available.